Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.7293 USD | +4.08% |
|
-2.76% | -30.54% |
Jun. 26 | Transcript : Quince Therapeutics, Inc. - Special Call | |
Jun. 25 | Quince Therapeutics Doses First Patient in Phase 3 Trial of EryDex to Treat Ataxia-Telangiectasia | MT |
Business Summary
Number of employees: 32
Managers
Managers | Title | Age | Since |
---|---|---|---|
Dirk Thye
CEO | Chief Executive Officer | 54 | 22-05-18 |
Brendan Hannah
DFI | Director of Finance/CFO | 39 | 22-04-30 |
Charles Ryan
PSD | President | 59 | 23-08-31 |
Maureen M. Roden
CTO | Chief Tech/Sci/R&D Officer | - | 22-05-31 |
Stacy Roughan
IRC | Investor Relations Contact | - | - |
Gary Ward
PRN | Corporate Officer/Principal | - | 22-07-31 |
Human Resources Officer | - | - |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Una Ryan
BRD | Director/Board Member | 82 | 18-02-28 |
Luca Benatti
BRD | Director/Board Member | 63 | 23-10-22 |
Dirk Thye
CEO | Chief Executive Officer | 54 | 22-05-18 |
David Lamond
CHM | Chairman | 49 | 15-11-30 |
Rajiv Patni
BRD | Director/Board Member | 55 | Feb. 14 |
Director/Board Member | 56 | 19-02-28 | |
Director/Board Member | 60 | 15-11-30 | |
June Bray
BRD | Director/Board Member | 70 | 22-06-08 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 43,215,233 | 37,509,172 ( 86.80 %) | 0 | 86.80 % |
Company contact information
Quince Therapeutics, Inc.
611 Gateway Boulevard Suite 273
94080, South San Francisco
+
http://quincetx.com![address Quince Therapeutics, Inc.(QNCX)](https://cdn.zonebourse.com/static/address/58071836.png)
Sector
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-30.54% | 31.52M | |
+18.97% | 45.34B | |
+41.98% | 40.42B | |
-10.06% | 37.92B | |
+31.15% | 31.75B | |
-7.79% | 27.71B | |
+13.32% | 26.52B | |
+43.05% | 13.96B | |
+31.28% | 12.44B | |
-7.41% | 11.26B |
- Stock Market
- Equities
- QNCX Stock
- Company Quince Therapeutics, Inc.